Maynard Um
-
-
-
-
-
-
-
Foghorn advances three protein degrader programs toward clinical trials
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Foghorn Therapeutics (FHTX)
-
-
-
-
-
-
-
Foghorn Therapeutics (FHTX) says efficacy threshold not achieved to support continued development of FHD-286
-
-
-
-
-
-
-
GSK (GSK) and Flagship Pioneering partner to discover novel medicines and vaccines
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

